Please Wait.....
Report
Mexico Oncology Drugs Market
Market Report I 2025-11-01 I 350 Pages I Data Bridge Market Research
Mexico Oncology Drugs market is expected to reach USD 4.30 Million by 2032 from USD 1.88 Million in 2024, growing at a substantial CAGR of 10.9% in the forecast period of 2025 to 2032.
Market Segmentation:
Mexico Oncology Drugs market, By Drug Class (Cytotoxic drugs, Targeted Drugs, Immunotherapy, and Hormonal Drugs), Drugs Type (Branded and Generics), Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Thyroid Cancer, Lung cancer, Blood Cancer, Gastric Cancer, and Others), Route of Administration (Oral and Parenteral), Population Type (Children, Adults, and Geriatric), Gender (Female and Male), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCS), Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2032
Overview of Mexico Oncology Drugs market Dynamics :
Driver
- Increased adoption of immunotherapy & new treatment regimens
- Rising cancer incidence and morality
- Growing awareness & clinical evidence
Restraint
- High cost and affordability
- Fragmented and under-resourced health system
- Supply chain issues and drug shortages
Opportunity
- Rising healthcare expenditure and disposable income
- Increasing research and development activities
- Technological advancement in oncology drug development and delivery
Challenges
- Stringent rules & regulations
- Limited access, infrastructure, and distribution of oncology drugs
- Economic and institutional challenges in market substantiality
Market Players:
The key market players operating in the Mexico Oncology Drugs market are listed below:
- AstraZeneca (U.K.)
- Pfizer Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Amgen Inc. (U.S.)
- ARCHIMED (France)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- BeOne Medicines (China)
- Boehringer Ingelheim International GmbH (Germany)
- Daiichi Sankyo Company, Limited (Japan)
- Eisai Co., Ltd. (Japan)
- FANASA (Mexico)
- Florencia Healthcare (India)
- Glenmark Pharmaceuticals Ltd. (India)
- Ipsen Pharma (France)
- Johnson & Johnson and its Affiliates (U.S.)
- Knight Therapeutics Inc. (Canada)
- Marzam (Mexico)
- Nadro (Mexico)
- ONCO ESPECIALIZADOS (Mexico)
- PISA (Mexico)
- Probemedic Distribuciones, S.A. de C.V. (Mexico)
- Sanofi (France)
TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF MEXICO ONCOLOGY DRUGS MARKET 19
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.8 DBMR MARKET POSITION GRID 35
2.9 MARKET END USER COVERAGE GRID 36
2.10 SECONDARY SOURCES 37
2.11 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 45
4.1 PESTAL ANALYSIS 46
4.2 PORTER'S FIVE FORCES ANALYSIS 47
4.3 PIPELINE ANALYSIS - MEXICO ONCOLOGY DRUGS MARKET 48
4.3.1 PHASE DISTRIBUTION 48
4.3.2 KEY TRENDS IN THE EXPANDED PIPELINE 48
4.3.3 GEOGRAPHICAL AND INSTITUTIONAL TRENDS 49
4.3.4 STRATEGIC INSIGHTS 49
4.4 MERGERS AND ACQUISITIONS 50
4.4.1 LICENSING 50
4.4.2 COMMERCIALIZATION AGREEMENTS 50
4.5 DRUG TREATMENT RATE IN MATURED MARKETS 52
4.5.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
4.5.2 PATIENT FLOW DIAGRAM 52
4.5.3 KEY PRICING STRATEGIES 52
4.5.4 KEY PATIENT ENROLLMENT STRATEGIES 53
4.5.5 INTERVIEWS WITH SPECIALISTS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 PATIENT TREATMENT SUCCESS RATES 55
6 REGULATION COVERAGE. 56
6.1 NORTH AMERICA 56
6.1.1 PRODUCT CODES 56
6.1.2 CERTIFIED STANDARDS 56
6.1.3 SAFETY STANDARDS 56
6.1.3.1 MATERIAL HANDLING & STORAGE 57
6.1.3.2 TRANSPORT & PRECAUTIONS 57
6.1.3.3 HAZARD IDENTIFICATION 57
6.1.4 REGULATION COVERAGE - MEXICO ONCOLOGY DRUGS MARKET 58
6.1.4.1 PRODUCT CODES 58
6.1.4.2 CERTIFIED STANDARDS 59
6.1.5 SAFETY STANDARDS 60
6.1.5.1 MATERIAL HANDLING & STORAGE 60
6.1.5.2 TRANSPORT & PRECAUTIONS 60
6.1.5.3 1HAZARD IDENTIFICATION 61
6.1.6 VARIATION IN REGULATIONS BASED ON ONCOLOGY DRUG TYPES 62
6.1.6.1 SMALL MOLECULE CHEMOTHERAPY AGENTS 62
6.1.7 BIOLOGICS (MONOCLONAL ANTIBODIES, CYTOKINES, CELL-BASED THERAPIES) 62
6.1.7.1 BIOSIMILARS 63
6.1.7.2 IMMUNOTHERAPIES (CHECKPOINT INHIBITORS, CYTOKINE THERAPIES) 63
6.1.7.3 ADVANCED THERAPIES (GENE THERAPY, CAR-T CELLS) 63
7 MEXICO ONCOLOGY DRUG MARKET: MARKET OVERVIEW 65
7.1 DRIVER 67
7.1.1 INCREASED ADOPTION OF IMMUNOTHERAPY & NEW TREATMENT REGIMENS 67
7.1.2 RISING CANCER INCIDENCE AND MORTALITY 68
7.1.3 GROWING AWARENESS & CLINICAL EVIDENCE 68
7.2 RESTRAINTS 69
7.2.1 HIGH COST AND AFFORDABILITY 69
7.2.2 FRAGMENTED AND UNDER-RESOURCED HEALTH SYSTEM 69
7.2.3 SUPPLY CHAIN ISSUES AND DRUG SHORTAGES 70
7.3 OPPORTUNITIES 71
7.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 71
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 72
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN ONCOLOGY DRUG DEVELOPMENT AND DELIVERY 72
7.3.4 STRINGENT RULES & REGULATIONS 73
7.3.5 LIMITED ACCESS, INFRASTRUCTURE, AND DISTRIBUTION OF ONCOLOGY DRUGS 73
7.3.6 ECONOMIC AND INSTITUTIONAL CHALLENGES IN MARKET SUSTAINABILITY 74
8 MEXICO ONCOLOGY DRUGS MARKET, BY DRUG CLASS 75
8.1 OVERVIEW 76
8.2 TARGETED DRUGS 79
8.2.1 MONOCLONAL ANTIBODIES 80
8.2.1.1 TRASTUZUMAB 80
8.2.1.2 BEVACIZUMAB 80
8.2.1.3 RITUXIMAB 80
8.2.1.4 OFATUMUMAB 80
8.2.1.5 OBINUTUZUMAB 80
8.2.1.6 ALEMTUZUMAB 80
8.2.1.7 OTHERS 80
8.2.2 TYROSINE KINASE INHIBITORS 81
8.2.2.1 IMATINIB 81
8.2.2.2 DASATINIB 81
8.2.2.3 NILOTINIB 81
8.2.2.4 BOSUTINIB 81
8.2.2.5 SUNITINIB 81
8.2.2.6 PONATINIB 81
8.2.2.7 OTHERS 81
8.2.3 PROTEASOME INHIBITOR 82
8.2.3.1 BORTEZOMIB 82
8.2.3.2 CARFILZOMIB 82
8.2.3.3 OTHERS 82
8.2.4 OTHERS 82
8.3 CYTOTOXIC DRUGS 83
8.3.1 ALKYLATING AGENT 84
8.3.1.1 CISPLATIN 84
8.3.1.2 CARBOPLATIN 84
8.3.1.3 CYCLOPHOSPHAMIDE 84
8.3.1.4 MELPHALAN 84
8.3.1.5 CHLORAMBUCIL 84
8.3.1.6 OTHERS 84
8.3.2 ANTIMETABOLITES 85
8.3.2.1 METHOTREXATE 85
8.3.2.2 FLUOROURACIL 85
8.3.2.3 GEMCITABINE 85
8.3.2.4 CYTARABINE (ARA-C) 85
8.3.2.5 AZACITIDINE 85
8.3.2.6 FLUDARABINE 85
8.3.2.7 OTHERS 85
8.3.3 ANTIMITOTIC DRUGS 86
8.3.3.1 VINCRISTINE 86
8.3.3.2 VINBLASTINE 86
8.3.3.3 CABAZITAXEL 86
8.3.3.4 OTHERS 86
8.3.4 TOPOISOMERASE INHIBITORS (I AND II) 87
8.3.4.1 ANTHRACYCLINE 88
8.3.4.1.1 DOXORUBICIN 88
8.3.4.1.2 DAUNORUBICIN 88
8.3.4.1.3 IDARUBICIN 88
8.3.4.1.4 OTHERS 88
8.3.4.2 ETOPOSIDE 88
8.3.4.3 IRINOTECAN 88
8.3.4.4 TOPOTECAN 88
8.3.4.5 OTHERS 88
8.4 IMMUNOTHERAPY 89
8.4.1 CAR T-CELL THERAPY 89
8.4.1.1 AXICABTAGENE CILOLEUCEL 90
8.4.1.2 TISAGENLECLEUCEL 90
8.4.1.3 BREXUCABTAGENE AUTOLEUCEL 90
8.4.1.4 OTHERS 90
8.4.2 IMMUNOMODULATORY DRUGS (IMIDS) 90
8.4.2.1 LENALIDOMIDE 90
8.4.2.2 POMALIDOMIDE 90
8.4.2.3 THALIDOMIDE 90
8.4.3 CYTOKINES 91
8.4.3.1 INTERFERONS 91
8.4.3.1.1 INTERFERON ALFA-2B 91
8.4.3.1.2 INTERFERON ALFA-2A 91
8.4.3.2 INTERLEUKINS (ILS) 91
8.4.4 OTHERS 91
8.5 HORMONAL DRUGS 92
8.5.1 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) 92
8.5.1.1 TAMOXIFEN (NOLVADEX) 92
8.5.1.2 TOREMIFENE (FARESTON) 92
8.5.2 ESTROGEN PRODUCTION BLOCKERS 93
8.5.2.1 LETROZOLE 93
8.5.2.2 ANASTROZOLE 93
8.5.2.3 EXEMESTANE 93
8.5.2.4 OTHERS 93
8.5.3 OTHER ANTIESTROGEN DRUGS 93
8.5.4 OVARIAN FUNCTION BLOCKERS 94
8.5.4.1 GOSERELIN 94
8.5.4.2 LEUPRORELIN 94
8.5.4.3 TRIPTORELIN 94
8.6 OTHERS 94
9 MEXICO ONCOLOGY DRUGS MARKET, BY DRUGS TYPE 95
9.1 OVERVIEW 96
9.2 BRANDED 99
9.3 GENERICS 99
10 MEXICO ONCOLOGY DRUGS MARKET, BY TYPE 100
10.1 OVERVIEW 101
10.2 LUNG CANCER 106
10.2.1 TARGETED DRUGS 106
10.2.2 CYTOTOXIC DRUGS 106
10.2.3 IMMUNOTHERAPY 106
10.2.4 HORMONAL DRUGS 106
10.3 BREAST CANCER 107
10.3.1 TARGETED DRUGS 107
10.3.2 HORMONAL DRUGS 107
10.3.3 CYTOTOXIC DRUGS 107
10.3.4 IMMUNOTHERAPY 107
10.4 BLOOD CANCER 108
10.4.1 LEUKEMIA 108
10.4.2 NON-HODGKIN LYMPHOMA 108
10.4.3 MULTIPLE MYELOMA 108
10.4.4 HODGKIN LYMPHOMA 108
10.4.5 TARGETED DRUGS 109
10.4.6 CYTOTOXIC DRUGS 109
10.4.7 IMMUNOTHERAPY 109
10.4.8 HORMONAL DRUGS 109
10.5 COLORECTAL CANCER 110
10.5.1 IMMUNOTHERAPY 110
10.5.2 CYTOTOXIC DRUGS 110
10.5.3 TARGETED DRUGS 110
10.5.4 HORMONAL DRUGS 110
10.6 PROSTATE CANCER 111
10.6.1 HORMONAL DRUGS 111
10.6.2 TARGETED DRUGS 111
10.6.3 CYTOTOXIC DRUGS 111
10.6.4 IMMUNOTHERAPY 111
10.7 LIVER CANCER 112
10.7.1 TARGETED DRUGS 112
10.7.2 CYTOTOXIC DRUGS 112
10.7.3 IMMUNOTHERAPY 112
10.7.4 HORMONAL DRUGS 112
10.8 PANCREATIC CANCER 113
10.8.1 TARGETED DRUGS 113
10.8.2 CYTOTOXIC DRUGS 113
10.8.3 IMMUNOTHERAPY 113
10.8.4 HORMONAL DRUGS 113
10.9 KIDNEY CANCER 114
10.9.1 TARGETED DRUGS 114
10.9.2 CYTOTOXIC DRUGS 114
10.9.3 IMMUNOTHERAPY 114
10.9.4 HORMONAL DRUGS 114
10.10 GASTRIC CANCER 115
10.10.1 CYTOTOXIC DRUGS 115
10.10.2 TARGETED DRUGS 115
10.10.3 IMMUNOTHERAPY 115
10.10.4 HORMONAL DRUGS 115
10.11 ENDOMETRIAL CANCER 116
10.11.1 CYTOTOXIC DRUGS 116
10.11.2 TARGETED DRUGS 116
10.11.3 HORMONAL DRUGS 116
10.11.4 IMMUNOTHERAPY 116
10.12 THYROID CANCER 117
10.12.1 TARGETED DRUGS 117
10.12.2 CYTOTOXIC DRUGS 117
10.12.3 IMMUNOTHERAPY 117
10.12.4 HORMONAL DRUGS 117
10.13 OTHERS 118
10.13.1 TARGETED DRUGS 118
10.13.2 CYTOTOXIC DRUGS 118
10.13.3 IMMUNOTHERAPY 118
10.13.4 HORMONAL DRUGS 118
11 MEXICO ONCOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 119
11.1 OVERVIEW 120
11.2 PARENTERAL 123
11.3 ORAL 124
11.3.1 TABLETS 124
11.3.2 CAPSULE 124
11.3.3 PILL 124
11.3.4 OTHERS 124
12 MEXICO ONCOLOGY DRUGS MARKET, BY POPULATION TYPE 125
12.1 OVERVIEW 126
12.2 GERIATRIC 129
12.3 ADULTS 129
12.4 CHILDREN 129
13 MEXICO ONCOLOGY DRUGS MARKET, BY GENDER 130
13.1 OVERVIEW 131
13.2 MALE 134
13.3 FEMALE 134
14 MEXICO ONCOLOGY DRUGS MARKET, BY END USER 135
14.1 OVERVIEW 136
14.2 HOSPITAL 139
14.2.1 PUBLIC 139
14.2.2 PRIVATE 139
14.3 SPECIALTY CLINICS 140
14.4 AMBULATORY SURGICAL CENTERS 140
14.5 HOME HEALTHCARE 140
14.6 OTHERS 140
15 MEXICO ONCOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 141
15.1 OVERVIEW 142
15.2 DIRECT TENDER 145
15.3 RETAIL SALES 145
15.3.1 HOSPITALS PHARMACY 146
15.3.2 RETAIL PHARMACY 146
15.3.3 ONLINE PHARMACY 146
15.4 OTHERS 146
16 MEXICO ONCOLOGY DRUGS MARKET, COMPANY LANDSCAPE 147
16.1 MANUFACTURER COMPANY SHARE ANALYSIS: MEXICO 147
16.2 DISTRIBUTOR COMPANY SHARE ANALYSIS: MEXICO 148
17 SWOT ANALYSIS 149
18 COMPANY PROFILES 150
18.1 ASTRAZENECA 150
18.1.1 COMPANY SNAPSHOT 150
18.1.2 REVENUE ANALYSIS 151
18.1.3 PRODUCT PORTFOLIO 151
18.1.4 RECENT DEVELOPMENT 153
18.2 PFIZER INC. 154
18.2.1 COMPANY SNAPSHOT 154
18.2.2 REVENUE ANALYSIS 154
18.2.3 PRODUCT PORTFOLIO 155
18.2.4 RECENT DEVELOPMENT 156
18.3 BRISTOL-MYERS SQUIBB COMPANY 157
18.3.1 COMPANY SNAPSHOT 157
18.3.2 REVENUE ANALYSIS 158
18.3.3 PRODUCT PORTFOLIO 158
18.3.4 RECENT NEWS 161
18.4 ESTEVE 162
18.4.1 COMPANY SNAPSHOT 162
18.4.2 REVENUE ANALYSIS 162
18.4.3 PRODUCT PORTFOLIO 162
18.4.4 RECENT DEVELOPMENT 162
18.5 NOVARTIS AG 163
18.5.1 COMPANY SNAPSHOT 163
18.5.2 REVENUE ANALYSIS 163
18.5.3 PRODUCT PORTFOLIO 164
18.5.4 RECENT DEVELOPMENT 167
18.6 F. HOFFMANN-LA ROCHE LTD. 168
18.6.1 COMPANY SNAPSHOT 168
18.6.2 REVENUE ANALYSIS 168
18.6.3 PRODUCT PORTFOLIO 169
18.6.4 RECENT DEVELOPMENT 172
18.7 MERCK & CO., INC. 173
18.7.1 COMPANY SNAPSHOT 173
18.7.2 REVENUE ANALYSIS 173
18.7.3 PRODUCT PORTFOLIO 174
18.7.4 RECENT DEVELOPMENT 176
18.8 ABBVIE INC. 177
18.8.1 COMPANY SNAPSHOT 177
18.8.2 REVENUE ANALYSIS 177
18.8.3 PRODUCT PORTFOLIO 178
18.8.4 RECENT DEVELOPMENTS 179
18.9 AMGEN INC. 181
18.9.1 COMPANY SNAPSHOT 181
18.9.2 REVENUE ANALYSIS 181
18.9.3 PRODUCT PORTFOLIO 182
18.9.4 RECENT DEVELOPMENTS 186
18.10 ARCHIMED 188
18.10.1 COMPANY SNAPSHOT 188
18.10.2 PRODUCT PORTFOLIO 188
18.10.3 RECENT DEVELOPMENTS 188
18.11 ASTELLAS PHARMA INC. 189
18.11.1 COMPANY SNAPSHOT 189
18.11.2 REVENUE ANALYSIS 190
18.11.3 PRODUCT PORTFOLIO 190
18.11.4 RECENT DEVELOPMENT 192
18.12 BAYER AG 194
18.12.1 COMPANY SNAPSHOT 194
18.12.2 REVENUE ANALYSIS 194
18.12.3 PRODUCT PORTFOLIO 195
18.12.4 RECENT DEVELOPMENT 196
18.13 BEONE MEDICINES 197
18.13.1 COMPANY SNAPSHOT 197
18.13.2 REVENUE ANALYSIS 197
18.13.3 PRODUCT PORTFOLIO 198
18.13.4 RECENT DEVELOPMENTS 199
18.14 BOEHRINGER INGELHEIM GMBH 201
18.14.1 COMPANY SNAPSHOT 201
18.14.2 REVENUE ANALYSIS 201
18.14.3 PRODUCT PORTFOLIO 202
18.14.4 RECENT DEVELOPMENT 202
18.15 DAIICHI SANKYO COMPANY, LIMITED. 203
18.15.1 COMPANY SNAPSHOT 203
18.15.2 REVENUE ANALYSIS 203
18.15.3 PRODUCT PORTFOLIO 204
18.15.4 RECENT DEVELOPMENT 205
18.16 EISAI CO., LTD. 206
18.16.1 COMPANY SNAPSHOT 206
18.16.2 REVENUE ANALYSIS 206
18.16.3 PRODUCT PORTFOLIO 207
18.16.4 RECENT DEVELOPMENT 207
18.17 FANASA 208
18.17.1 COMPANY SNAPSHOT 208
18.17.2 PRODUCT PORTFOLIO 208
18.17.3 RECENT DEVELOPMENTS 209
18.18 FLORENCIA HEALTHCARE 210
18.18.1 COMPANY SNAPSHOT 210
18.18.2 PRODUCT PORTFOLIO 210
18.18.3 RECENT DEVELOPMENT 213
18.19 GLENMARK PHARMACEUTICALS LTD. 214
18.19.1 COMPANY SNAPSHOT 214
18.19.2 REVENUE ANALYSIS 215
18.19.3 PRODUCT PORTFOLIO 215
18.19.4 RECENT DEVELOPMENTS 218
18.20 IPSEN PHARMA 220
18.20.1 COMPANY SNAPSHOT 220
18.20.2 REVENUE ANALYSIS 220
18.20.3 PRODUCT PORTFOLIO 221
18.20.4 RECENT DEVELOPMENT 223
18.21 JOHNSON & JOHNSON AND ITS AFFILIATES 224
18.21.1 COMPANY SNAPSHOT 224
18.21.2 REVENUE ANALYSIS 225
18.21.3 PRODUCT PORTFOLIO 225
18.21.4 RECENT DEVELOPMENT/NEWS 227
18.22 KNIGHT THERAPEUTICS INC. 228
18.22.1 COMPANY SNAPSHOT 228
18.22.2 REVENUE ANALYSIS 228
18.22.3 PRODUCT PORTFOLIO 229
18.22.4 RECENT DEVELOPMENTS 230
18.23 MARZAM 232
18.23.1 COMPANY SNAPSHOT 232
18.23.2 PRODUCT PORTFOLIO 232
18.23.3 RECENT DEVELOPMENTS 233
18.24 NADRO 234
18.24.1 COMPANY SNAPSHOT 234
18.24.2 PRODUCT PORTFOLIO 234
18.24.3 RECENT DEVELOPMENTS 235
18.25 ONCO ESPECIALIZADOS 236
18.25.1 COMPANY SNAPSHOT 236
18.25.2 PRODUCT PORTFOLIO 236
18.25.3 RECENT DEVELOPMENT 236
18.26 PISA 237
18.26.1 COMPANY SNAPSHOT 237
18.26.2 PRODUCT PORTFOLIO 238
18.26.3 RECENT DEVELOPMENTS 239
18.27 PROBEMEDIC DISTRIBUCIONES, SA DE CV 240
18.27.1 COMPANY SNAPSHOT 240
18.27.2 PRODUCT PORTFOLIO 240
18.27.3 RECENT DEVELOPMENT 241
18.28 SANOFI 242
18.28.1 COMPANY SNAPSHOT 242
18.28.2 REVENUE ANALYSIS 243
18.28.3 PRODUCT PORTFOLIO 243
18.28.4 RECENT DEVELOPMENT 245
19 QUESTIONNAIRE 247
20 RELATED REPORTS 250
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security